Remarkably, the loss of BRCA2 function renders ovarian cancer cells with a more stable β-catenin, and these cells respond to Wnt treatment by preferential upregulation of the negative regulator Axin2 (Fig. 7). The gene discussed is AXIN2; the disease is ovarian carcinoma.